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Introduction: Immune checkpoint blockade is being investigated in 
clinical trials and showed great potential in lung cancer. The prognos-
tic roles of and clinicopathological factors associated with immune 
checkpoint gene expression, CTLA-4 and PDCD1 remain largely 
undefined, which encodes cytotoxic-lymphocyte antigen 4 (CTLA-4) 
and programmed cell death 1 (PD-1), respectively.
Methods: We used a lung cancer database of 1715 patients measured 
by Affymetrix microarrays to analyze the association of gene expres-
sion with clinicopathological factors and survival. Hazard ratio (HR) 
and 95% confidence interval (CI) for overall survival (OS) were calcu-
lated. Cutoffs were determined by median across the entire database.
Results: In 909 patients with histology information, significantly 
higher PDCD1 and CTLA-4 expression were found in squamous 
carcinoma than adenocarcinoma. In 848 patients with known smok-
ing history, current/former smokers were found to have significantly 
elevated gene expression compared with nonsmokers. Significant 
higher expression of both genes were found in TNM stage II ver-
sus I. Higher expression of PDCD1 predicted worse OS in univari-
ate analysis, but not in multivariate (HR: 1.22; 95% CI: 0.53–2.79). 
CTLA-4 was marginally significant in univariate analysis of the entire 
set (HR: 1.15; 95% CI: 0.99–1.34). In patients with information for 
multivariate analysis, higher expression of CTLA-4 was associated 
with worse OS (HR: 1.96; 95% CI: 1.18–3.31).
Conclusions: In this study with large number of patients, PDCD1 and 
CTLA-4 expression is significantly higher in squamous carcinoma 
and current/former smokers. Higher expression of CTLA-4, but not 
PDCD1 predicts worse survival.
Key Words: Non–small-cell lung cancer, Immune checkpoint 
blockade, PDCD1, CTLA-4, Smoking, Squamous carcinoma, 
Adenocarcinoma, Prognosis, Microarray
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Non–small-cell lung cancer (NSCLC) is one of the leading cancer death causes in the world. Despite recent prog-
ress and newly approved drugs, prognosis of advanced stage 
patients undergoing systemic therapy are still suboptimal and 
new treatment option is needed. Recent clinical trials with 
immune checkpoint blockade have shown promising results.1 
A subgroup of patients has been reported to have achieved 
durable long-term response, suggesting the potential of such 
paradigm.
To avoid autoimmune reaction to normal tissues, human 
body utilizes the immune checkpoint to balance the pro- and 
anti-immune reactions.2 Cancer cells have been known to 
hijack the immunosuppressive mechanism to evade the attack 
from immune system.3 Among the checkpoint pathways, cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) and pro-
grammed cell death 1 (PD-1) pathways are mostly studied. 
They are expressed on T cells and prevent the activation of 
cytotoxic T cells to function, with or without the interaction 
with its ligands.4 Blocking these two pathways tip the balance 
from tumor immune tolerance to immune activation.
It has been reported that CTLA-4, PD-1, and PD-ligand 
1 (PD-L1) were overexpressed in NSCLC, and correlated 
with poor survival in NSCLC patients. However, those studies 
mostly used immunohistochemistry (IHC) and enrolled small 
number of patients.5–11 Antibodies and cutoffs varied greatly as 
well. Larger studies are required to define the prognostic roles.
Early phases of clinical trials have shown promising 
results of CTLA-4 and PD-1/PD-L1 pathway blockade, and 
a subgroup of patients seemed to respond better to the block-
ade. Pretreatment patient selection for immune checkpoint 
blockade is being advocated. In a randomized phase II trial, 
squamous NSCLC than nonsquamous are more responsive to 
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ipilimumab, a CTLA-4 antibody.12 Gettinger et al.13 reported 
that patients with positive IHC PD-L1 staining have higher 
objective response rate to nivolumab (a PD-1 antibody), 
than those with negative staining. Both nivolumab14 and 
MPDL3280A15 (a PD-L1 antibody) have been reported to be 
more active in current/former smokers than in never-smokers.
To explore the clinicopathological factors associated 
with CTLA-4 and PDCD-1 gene expression, which encodes 
CTLA-4, and PD-1, respectively, and the prognostic roles 
in NSCLC, we utilized a large microarray database,16 which 
integrated data from the Cancer Biomedical Informatics 
Grid (caBIG), the Gene Expression Omnibus (GEO), and the 
Cancer Genome Atlas for lung cancers (TCGA).
MATERIALS AND METHODS
Online Microarray Database
Details of how the database (www.kmplot.com/lung) 
was constructed were described previously.16 In brief, data 
were extracted and integrated from caArray, GEO, and TCGA. 
Only tumor tissue was analyzed in all the original datasets. 
Clinical data from the three datasets including age, sex, smok-
ing history, histology, stage, grade, and survival, etc. were 
inputted into the online database. The smoking history was 
directly obtained from the datasets and was categorized into 
never-smokers and former/current smokers.
Datasets included in the online database are as fol-
lows: GSE457317, GSE1481418, GSE889419, GSE1918820, 
GSE314121, GSE312022, caArray,23 TCGA,24 GSE2901325, and 
GSE3774526. Detailed treatment information for each patient 
is not available.
Data Retrieval from the Online Database
Data retrieval was performed on August 2014. Gene 
expression cutoff value was chosen as median over entire data-
set to ensure all analyses of each gene was based on the same 
cutoff value. All available follow-up data were used. Biased 
arrays were excluded. Biased arrays were defined as those 
having two or more of following parameters out of the 95% 
range of all arrays, percentage of present calls, raw Q value, 
presence of bioB-/C-/D-spikes, GAPDH, and ACTB 3:5 ratio. 
Not all clinicopathological data were available in each patient, 
but all available data were reported.
Statistical Analysis
Gene expression level was compared using Mann–
Whitney U test (two cohorts comparison) or Kruskal–Wallis 
test (two or more cohorts comparison). The online database 
identified that histology, stage, sex, and smoking history are 
associated with overall survival (OS) by univariate analysis, 
but the above information was not available in all patients. 
Multivariate analysis of survival was carried out when gene 
expression is significantly associated with survival in patients 
with all the above-mentioned clinicopathological factors 
available (Uni in Multi in Table 2). All multivariate analysis 
was performed including histology, stage, sex, and smoking 
history by the online tool using Cox regression Kaplan–Meier 
survival curve was plotted and analyzed by logrank test.
RESULTS
Patient Characteristics and Gene Expression
Of 1715 patients in the database, 1432 patients had 
OS data. Median OS was 40 months. Median follow-up was 
37 months. Clinicopathological data were not available for 
all patients. Altogether, 556 and 500 patients were adeno-
carcinoma (Adeno) and squamous cell carcinoma (Squa), 
respectively; 441, 186, 67, and four patients were stage I, 
II, III, and IV; 634 were woman, whereas 908 were men; 
187 patients were never-smokers, in contrast to 689 current/
previous smokers.
For PDCD1, the median expression value was 65, with 
a range of 2 to 760 across the entire database (Fig. 1A). For 
CTLA-4, the median value was 95, with a range of 2 to 689 
(Fig. 1B). Interestingly, median PDCD1 expression value was 
36 in adenocarcinoma, compared with 78 in squamous car-
cinoma (p < 0.01; Fig. 2A; Table 1). Similarly, the median 
CTLA-4 was also higher in squamous cancer patients com-
pared with adenocarcinoma (median: 63 vs. 111; p < 0.01; 
Fig. 2A; Table 1).
Current/previous smokers had much higher PDCD1 and 
CTLA-4 expression compared with never-smokers (PDCD1 
median 142 vs. 36, p < 0.01; CTLA-4 median 152 vs. 59, p < 
0.01, Fig. 2B).
Gene expression in TNM stages I, II, and III patients 
was compared in 693 patients. Stage IV patients were 
excluded because only four stage IV patients were in the 
database. PDCD1 expression was progressively higher as 
TNM stage rises. The median was 43, 73, and 90 for stages 
I, II, and III patients, respectively (p < 0.01; Fig.2C). Similar 
trend was also observed in CTLA-4. The median expression 
value was 80, 107, and 115 in stages I, II, and III, respec-
tively (p < 0.01; Fig. 2C). The statistical significance was not 
found between stages II and III patients, likely due to insuf-
ficient sample size.
No difference of gene expression was found in different 
sex. The median of PDCD1 was 95 and 99 for woman and men, 
respectively. For CTLA-4, the median was 110 and 108 (Fig. 2D).
Association of Gene Expression with Survival
Using the median as cutoff value, the number of 
patients with lower PDCD1 expression was 629, and the 
number with higher was 803 (Table 2). Higher expression of 
PDCD1 was significantly correlated with worse OS (hazard 
ratio [HR]: 1.29, 95% confidence interval [CI]: 1.22–1.50) 
in univariate analysis (Table 2; Fig. 1C). Less data were 
available for multivariate analysis with a patient number of 
412 patients, and the HR was 1.22 (95% CI: 0.53–2.79). For 
412 patients, the univariate HR was 1.29 (95% CI: 1.11–1.5; 
Table 2).
Using the median as cutoff value, the number of patients 
with lower CTLA-4 expression was 646, and that with higher 
expression was 786 (Table 2; Fig. 2D). Univariate analysis of 
the entire patient cohort suggested a trend of correlation with 
OS (HR: 1.15, 95% CI: 0.99–1.34). However, in 412 patients 
with available data for multivariate analysis, the univariate 
analysis showed significant correlation with OS (HR: 3.46, 
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95% CI: 2.34–5.11). The correlation remained significant in 
multivariate analysis in this subgroup patient, with an HR of 
1.96 (95% CI: 1.18–3.31).
In squamous cancer patients, neither higher expression of 
PDCD1 (HR: 0.9, 95% CI: 0.69–1.18) nor CTLA-4 (HR: 0.91, 
95% CI: 0.7–1.19) was correlated with worse OS (Table 2). In 
FIGURE 1.  Gene expression (A, B) and overall survival curves (C, D). Red dots and curves High expression; black dots and curves 
low expression. PDCD1 is shown in A, B; CTLA-4 is shown in C, D.
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contrast, both genes were significantly correlated with OS in ade-
nocarcinoma patients. The HR was 1.8 (95% CI: 1.31–2.49) for 
PDCD1 and 1.57 (95% CI: 1.16–2.13) for CTLA-4, respectively.
In 178 never-smokers, higher expression of PDCD1 and 
CTLA-4 was significantly correlated with poorer OS (PDCD1: 
HR: 4.78, 95% CI: 2.53–9.01; CTLA-4: HR, 2.87, 95% CI: 
1.55–5.33). Although PDCD1 was still significant in smok-
ers (HR: 1.7, 95% CI: 1.27–2.27), CTLA-4 was found to 
have trend of association with survival (HR: 1.19, 95% CI: 
0.93–1.52), probably due to the sample size.
In stage I patients, both higher expression of PDCD1 
(HR: 2.14, 95% CI: 1.56–2.93) and CTLA-4 (HR: 2.12, 95% 
CI: 1.56–2.90) were significantly correlated with worse OS. 
The correlation was not significant in stage II patients, which 
was likely due to less number of patients.
Higher expression of the PDCD1 was significantly 
correlated with poorer OS. The HRs were 1.54 (95% CI: 
1.18–2.01) in woman, and 1.28 (95% CI: 1.05–1.57) in men. 
For CTLA-4, the HR was 1.33 (95% CI: 1.02–1.73) in woman, 
and 1.12 (95% CI: 0.91–1.36) in men.
TABLE 1.  Gene Expression Based on Clinicopathological Factors
PDCD1 CTLA-4
Median 95% CI Patient Number p Value Median 95% CI Patient Number p Value
Histology
  Adeno 36 7.15 487 <0.01 63 7.38 487 <0.01
  Squa 78 10.32 422 111 11.35 422
 Smoking history
  No 36 12.71 178 <0.01 59 13.31 178 <0.01
  Yes 142 8.6 670 152 10.07 670
 TNM stage
  I 43 9.25 441 <0.01 80 9.57 441 <0.01
  II 73 16.49 185 107 17.52 185
  III 90 28.55 67 115 32.88 67
Sex
  Woman 95 8.59 574 0.86 110 9.05 574 0.72
  Men 99 7.65 747 108 8.21 747
















  Univariate 629 803 1.29 1.22–1.50 646 786 1.15 0.99–1.34
  Uni in Multi 234 178 3.60 2.44–5.31 223 189 3.46 2.34–5.11
  Multivariate 234 178 1.22 0.53–2.79 223 189 1.96 1.18–3.31
Histology
  Ad 376 111 1.80 1.31–2.49 345 142 1.57 1.16–2.13
  Sq 192 230 0.90 0.69–1.18 180 242 0.91 0.7–1.19
Stage
  I 285 156 2.14 1.56–2.93 251 190 2.12 1.56–2.9
  II 88 97 1.43 0.93–2.2 75 110 1.3 0.84–2
Smoking history
  No 125 53 4.78 2.53–9.01 127 51 2.87 1.55–5.33
  Yes 193 477 1.7 1.27–2.27 235 435 1.19 0.93–1.52
Sex
  Woman 254 320 1.54 1.18–2.01 252 322 1.33 1.02–1.73
  Men 309 438 1.28 1.05–1.57 323 424 1.12 0.91–1.36
Uni, univariate analysis; Multi, multivariate analysis; Uni in Multi, univariate analysis performed with data available for multivariate analysis.
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DISCUSSION
In this study with larger number of patients, we dem-
onstrated that significantly higher PDCD1 and CTLA-4 
expression were found in squamous carcinoma than adenocar-
cinoma. Current/former smokers were found to have signifi-
cantly elevated gene expression compared with nonsmokers. 
Significantly higher expression of both the genes were found 
in TNM stage II versus I. Higher expression of PDCD1 is not 
associated with poorer survival in multivariate analysis (HR: 
1.22, 95% CI: 0.53–2.79), but higher CTLA-4 was associated 
with poorer survival (HR: 1.96, 95% CI: 1.18–3.31).
Distinct from direct cytotoxic effect of traditional che-
motherapy, the rationale of immune checkpoint blockade is 
to unleash the suppressed immunity in tumors and to allow 
host cytotoxic T cells to attack the tumor cells.2 Programmed 
death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-
4) pathways are the mostly studied ones in current NSCLC 
clinical trials. PD-1 and CTLA-4 are encoded by PDCD1 and 
CTLA-4 gene, respectively, and are expressed on activated T 
cells, the latter of the two is also constitutively expressed on 
immunosuppressive Treg cells.27 When the ligands of the two 
receptors interact with them, cytotoxic tumoricidal effect of T 
cells is inhibited. This immune evasive mechanism has been 
known to be hijacked by many kinds of tumors, including 
NSCLC, where upregulation of the immune checkpoint axis 
has been reported.6,28
Although clinical trials with immune checkpoint inhibi-
tors showed promising results, not all patients have been 
benefited and the need of patient selection for personalized 
treatment is being advocated. Recent data showed that patients 
with upregulation of the immune checkpoint axis before treat-
ment may have higher response. Indeed, stronger expression 
of PD-L1 IHC staining, the ligand of PD-1 appeared to pre-
dict better outcomes to PD-1/PD-L1 blockade. In NSCLC 
patients treated with pembrolizumab, strong PD-L1 staining 
predicts high response rate using two different types of IHC 
assays.29 Similar results have been reported in nivolumab and 
MPDL3280A trials as well (reviewed in Table 1 of reference 
1). Interestingly, a recent article also demonstrated the predic-
tive role of PD-1/PD-L1 axis activation in melanoma.30
Therefore, the identification of patients with immune 
checkpoint axis activation before treatment would be impor-
tant for personalized treatment. This study, using a combined 
database of 1715 patients, the largest number to our knowl-
edge so far, demonstrated that PDCD1 and CTLA-4 expres-
sion were significantly higher in patients with smoking history 
than never-smokers, and in patients with squamous carcinoma 
than adenocarcinoma.
This finding may explain why patients with squamous 
carcinoma and smoking history seemed to be more responsive 
to the immune checkpoint inhibitors. A phase II study found 
that ipilimumab, a CTLA-4 antibody administered in a phased 
fashion with chemotherapy, improved predefined immune-
related progression-free survival.12 Subgroup analysis found 
that patients with squamous histology seemed to have ben-
efited more than nonsquamous patients in this phased fash-
ion compared with chemotherapy alone. Preliminary phase 
I trial of nivolumab, a PD-1 antibody reported that higher 
response rate in squamous than nonsquamous NSCLC (33% 
vs. 12%).31 Progression-free survival rate at 24 weeks seem 
to differ in two histology as well (33% in squamous vs. 22% 
in nonsquamous).32 Interestingly, the association of smoking 
history with better response has been suggested as well. More 
smokers than nonsmokers responded to MPDL3280A, an 
anti-PD-L1 antibody (26% vs. 10%).15 These interesting clini-
cal results are consistent with the higher immune checkpoint 
gene expression in our report.
The detailed biology underlying the differential expres-
sion of immune checkpoint genes in patients with different 
histology and smoking history remains largely undefined. One 
recent study has reported that IL-6 receptor, the activation of 
which leads to immune activation, is suppressed in squamous 
NSCLC tumor tissues compared with in adenocarcinoma.28 
Furthermore, administration of blocking antibody to IL-6 
receptor to murine lung cancer models significantly upregu-
lated a sets of immunosuppresive genes, including CTLA-4. 
More interestingly, tumor propagating cells in murine lung 
squamous cancer have been found to be enriched for PD-L1 
expression.33 Therefore, it is likely that squamous NSCLC is 
at a more immunosuppressive status than adenocarcinoma, 
consistent with worse survival of squamous patients in the 
whole database.16 Further studies are needed to clarify the 
intriguing mechanism.
In addition to the clinicopathological factors associated 
with higher PDCD1 and CTLA-4 expression, we also found 
that the expression levels of the two genes in stage I patients 
were also significantly higher compared with stage II patients, 
but not significant when comparing stages II and III, possi-
bly due to limited sample size. The results of prognostic roles 
showed that higher expression of PDCD1 was associated with 
worse survival in univariate analysis, but did not hold in mul-
tivariate. CTLA-4 was not significantly prognostic in the 1432 
patients in univariate analysis, but was significant in patients 
with available data for multivariate analysis. However, the rea-
son that why these markers are not prognostic in squamous 
patients is not clear. Perhaps, some other unidentified factors 
may play a role.
In previous studies, the association of immune check-
point expression with smoking history, squamous disease, 
and prognosis was not consistent, possibly due to smaller 
sample sizes, different assay methods, and cutoffs. PD-L1/
PD-L2 IHC 3+ was reported to be more frequently found in 
smokers in a cohort of KRAS-mutated NSCLC patients.34 The 
elevation of CTLA-4 and PD-1 on peripheral T cells has been 
reported in healthy smokers.35 However, Chen et al.36 reported 
that positive PD-L1 expression was negatively associated with 
smoking history in 208 NSCLC patients. A report using two 
cohorts found higher PD-L1 protein expression of squamous 
cancer in the Yale cohort, but not in the Greek cohort.6 The 
same study however did not show statistically significant dif-
ference between the squamous cancer and adenocarcinoma by 
mRNA expression, although a trend was suggested. Higher 
PD-L1 expression was found to predict better survival in 
this study too. In a study of 109 NSCLC patients, Mu et al.10 
reported higher PD-L1 staining in adenocarcinoma, and that 
higher staining predicted worse survival. A reduction of death 
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rate was found in higher CTLA-4 expression detected by tis-
sue microarray IHC, although not statistically significant.9
Given that immunotherapies other than immune check-
point blockade are also being actively investigated in NSCLC, 
it would be interesting in the future to use the microarray data 
to explore the utility and associated clinicopathological fac-
tors of other emerging markers as well. However, it looks like 
predictive markers in other kinds of immunotherapies seem 
to be much more complex. For example, an 84-gene signa-
ture has been tested to predict the efficacy of MAGE3 vaccine 
in NSCLC.37 It would be interesting to test multiple genes in 
the future when this online database become more powerful 
to analyze a gene signature. Recent updates of the database 
have included four more datasets, GSE5008138, GSE4258039, 
GSE3021940, and GSE31908 (unpublished).
This study still has some limitations. First, the retrospective 
nature cannot avoid the potential confounding biases despite the 
large sample size. Second, clinicopathological data and detailed 
treatment information were not available in all the patients. Third, 
the microarray data needs to be validated by quantitative poly-
merase chain reaction, although the database was a pool of sev-
eral independent microarray sets. It would be interesting if any 
of included patients received immune checkpoint inhibitors. 
However, to the best of our knowledge, tissue collection period 
in these studies was before the immune checkpoint drugs widely 
entered into clinical trials. Neither any of the original published 
paper provided information that any patients had been treated 
with immunotherapy. Therefore, to the best of our knowledge, the 
proportion of patients who were treated by immune checkpoint 
blockade or immunotherapy, if any, would be very low.
In summary, our study found that PDCD1 and CTLA-
4 gene expression levels are significantly higher in patients 
with squamous disease than adenocarcinoma, and are higher 
in current/former smokers than in never-smokers. Further pro-
spective studies with solid detecting methods are needed to 
confirm this observation and to explore whether it may guide 
personalized immune checkpoint blockade treatment for 
NSCLC patients. Higher CTLA-4, but not PDCD1 expression 
was associated with worse survival.
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